Amendments to the Claims:

This claim listing will replace all prior versions and listings of claims in the application:

Claim Listing:

1-17. Cancelled.

18. (Currently Amended) A method for inducing an immune response in a mammal, the method comprising administering to the mammal a compound comprising a CpG dinucleotide and an immunomodulatory moiety wherein the immunomodulatory moiety is selected from the group consisting of: one or more abasic nucleoside, 1,3-propanediol linker[[,]] which may be substituted or unsubstituted, 3'-3' linkage and a modified base-containing [[nucleosides]] nucleoside, wherein the modified base-containing nucleoside is selected from the group consisting of: inosine, 2-amino-purine, nebularine, 7-deaza-guanosine, nitropyrrole, nitroindole, deoxyuridine, 4-thio-deoxyuridine, d-isoguanosine, d-iso-5-methylcytosine and P-base; and wherein the compound has greater immunostimulatory effect than it would have if it lacked the immunomodulatory moiety.

19. (Original) The method according to claim 18, wherein the mammal is a human.

20. (Original) The method according to claim 18, wherein the administration of the compound is parenteral, oral, sublingual, transdermal, topical, intranasal, intratracheal, or intrarectal.

21. (Previously Amended) The method according to claim 18, wherein the compound is administered at a sufficient dosage to attain a blood level of oligonucleotide from about 0.01 micromolar to about 10 micromolar.

22. (Original) The method according to claim 18, wherein dosage of compound is from about 0.1mg per patient per day to about 200mg per kg body weight per day.

23. (Original) The method according to claim 18, wherein the compound is administered in combination with a vaccine.

24. (Previously Amended) The method according to claim 23, further comprising administering an adjuvant.

25-26. Cancelled.

27. (Previously Amended) The method according to claim 18, wherein G is selected from the group consisting of guanosine, 7-deazaguanosine and inosine.